Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Darren R. Feldman, James S Hu, Sujata Patil, Victor E. Reuter, Sandy Srinivas, Walter Michael Stadler, Brian Addis Costello, Matthew I. Milowsky, Leonard Joseph Appleman, Tanya B. Dorff, Maria Bromberg, Gabriella Joseph, Samuel Aaron Funt, Dean F. Bajorin, George J. Bosl, David I. Quinn, Robert J. Motzer
Institutions: Memorial Sloan Kettering Cancer Center, University of Southern California, USC Norris Comprehensive Cancer Center, Stanford Medicine, University of Chicago, Mayo Clinic, University of North Carolina at Chapel Hill, University of Pittsburgh Medical Center, City Of Hope National Medical Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947009654